Rutsch W
Abteilung für Kardiologie und Pneumologie, Universitätsklinikum Rudolf Virchow, Freie Universität Berlin.
Herz. 1992 Feb;17(1):50-63.
With intravenous thrombolysis mortality of acute myocardial infarction can be significantly reduced, not only in the first hours after the onset of symptoms, but also up to 24 hours. The open infarct related coronary artery is important concerning long-term clinical outcome. If thrombolysis can be administered within the first three to six hours, limitation of infarct size and preservation of left ventricular function contribute to an impressive reduction in mortality. Long-term assessments of clinical outcome have surprisingly shown that the prognosis is much more dependent upon patency of the infarct related artery than from the time to treatment. Since a correlation is suspected between the degree of residual stenosis and the clinical course, recurrence of ischemia, reinfarction, hemodynamic instability and death, and the fact that mortality is highest within the first three days after thrombolysis the emphasis of numerous investigations has been on possibilities of PTCA in the acute stage of myocardial infarction. The application of interventional techniques was tested at different times within the progression of myocardial infarction. PTCA can be applied as primary, direct therapy without thrombolysis, immediately and during intravenous thrombolysis, following successful pharmacological recanalisation, as rescue-PTCA for failed thrombolytic therapy, delayed and as a prophylactic measure up to until days after the infarction or later when accompanied by careful observation of the patient, when limited to few indications with spontaneous or stress-related angina pectoris, hemodynamic instability or predetermined angiographic criteria. Important results have been gathered by the larger studies of the last few years, TAMI, ECSG, and TIMI as well as by numerous smaller investigations, about the pathophysiology and treatment of myocardial infarction. Despite different study design, the three larger trials have come to the same conclusion regarding PTCA and rt-PA thrombolysis, early PTCA is without advantage compared to a deferred treatment; the acute results are usually worse and the clinical course more complicated. It must be mentioned however, that major problems still remain unresolved: primary or direct angioplasty, PTCA in combination with non-fibrin specific plasminogen activators, as well as rescue-PTCA after failed thrombolysis. Specially, 90 minutes after thrombolysis 23 to 44% of the coronaries are still occluded, depending on the plasminogen activator, and there is no non-invasive procedure to detect this patient-group and to advise further treatment. Due to the high mortality rate within the first three days attempts of treatment are concentrated on this time-span.(ABSTRACT TRUNCATED AT 400 WORDS)
静脉溶栓可显著降低急性心肌梗死的死亡率,不仅在症状发作后的最初数小时内有效,而且在长达24小时内都有效果。开通梗死相关冠状动脉对长期临床预后很重要。如果能在发病后的前三至六小时内进行溶栓,梗死面积的限制和左心室功能的保留有助于显著降低死亡率。令人惊讶的是,对临床预后的长期评估表明,预后更多地取决于梗死相关动脉的通畅情况,而非治疗时间。由于怀疑残余狭窄程度与临床病程、缺血复发、再梗死、血流动力学不稳定及死亡之间存在关联,且溶栓后头三天内死亡率最高,众多研究的重点一直是急性心肌梗死阶段进行经皮冠状动脉腔内血管成形术(PTCA)的可能性。在心肌梗死进展过程中的不同时间对介入技术的应用进行了测试。PTCA可作为不进行溶栓的直接初始治疗、在静脉溶栓期间及之后立即进行、在成功的药物再灌注后进行、作为溶栓治疗失败后的补救性PTCA、延迟进行以及作为预防性措施,直至梗死数天后或更晚,前提是对患者进行仔细观察,且仅限于少数有自发或与应激相关的心绞痛、血流动力学不稳定或预定血管造影标准的情况。过去几年的大型研究(如TAMI、ECSG和TIMI)以及众多小型研究已收集到关于心肌梗死病理生理学和治疗的重要结果。尽管研究设计不同,但这三项大型试验在PTCA和重组组织型纤溶酶原激活剂(rt-PA)溶栓方面得出了相同结论:与延迟治疗相比,早期PTCA并无优势;急性结果通常更差,临床病程更复杂。然而必须指出,主要问题仍未解决:直接血管成形术、PTCA与非纤维蛋白特异性纤溶酶原激活剂联合使用以及溶栓失败后的补救性PTCA。特别是,溶栓后90分钟,根据纤溶酶原激活剂的不同,仍有23%至44%的冠状动脉闭塞,且没有非侵入性方法来检测这部分患者并指导进一步治疗。由于头三天内死亡率很高,治疗尝试都集中在这个时间段。(摘要截选至400字)